See something missing? Fill out this form to add your event.
Webinar #28 – Modulating gene regulation to treat gene dosage-associated diseases
- This event has passed.
April 1, 2021 @ 1:00 pm – 2:00 pm EDT
In this video Dr Nadav Ahituv presents Modulating Gene Regulation to Treat Gene Dosage-Associated Diseases
Prof. Ahituv shared his labs work with us on April 1st. Prof. Ahituv is an advisor to two companies working to cure diseases like SYNGAP1: Encoded Therapeutics & Regel Therapeutics. His lab is also part of a team from across UCSF, UC Berkeley & the University of Washington that recently secured a grant from the Weill Neurohub. This grant was to look a haploinsufficencies and SYNGAP1 is one of the explicit targets.
Dr. Ahituv is a Professor in the Department of Bioengineering and Therapeutic Sciences and the Institute for Human Genetics at the University of California, San Francisco. He received his Ph.D. in human genetics from Tel-Aviv University working on hereditary hearing loss. He then did his postdoc, in functional genomics, at the Lawrence Berkeley National Laboratory and the Department of Energy Joint Genome Institute.
The Ahituv lab is focused on understanding the role of regulatory sequences in human biology and disease. Through a combination of comparative genomic strategies, biochemical assays, regulatory element analysis, human patient samples, mouse and fish genetic engineering technologies, and massively parallel reporter assays they are working to elucidate mechanisms whereby genetic variation within these sequences leads to changes in human phenotypes.
Transcript:
00:00 Welcome and Introduction to the work of Dr Nadav Ahituv
03:10 Overview of talk
04:27 Haploinsufficiency: When one functional copy of a gene is not enough
09:31 CRISPRa as a therapeutic for haploinsufficiency?
11:13 Sim1, an important obesity gene
14:44 CRISPRa for either Sim1 promotor or enhancer rescues the obesity phenotype
22:23 Can we develop it as a therapeutic?
23:35 Many genes cannot get packaged in an AAV
28:23 Summary
43:43 Q&A
THIS IS FOR TRANSCRIPT ONLY:
0:05Okay then, hello everyone and welcome to today’s session. My name is Marta Dahiya. I’m one of the
0:12Syngap parents. I’m part of the SynGAP Research Fund. We are excited again to have another webinar
0:20in the webinar series. The goal of the series is getting you closer to the science of Syngap,
0:26make you aware of the research that is being done and the opportunities to participate, and empower your communications with clinicians as you get clearer knowledge of Syngap. We also want to
0:38plug you into the next presentation that is An Integrated Approach to investigating GI and
0:46neurological co-morbidities caused by Syngap. This will take place on April 22nd at 1pm eastern time
0:54and is with Dr Jimenez, Dr Dalman, and Dr Mosher. Our talk today is Modulating Gene Regulation to
1:03Treat Gene Dose Associated Diseases. I have the pleasure to introduce today’s speaker Dr Nadav Ahituv.
1:13Dr Ahituv is a professor in the department of bioengineering and therapeutic science and the institute for
1:21human genetics at the University of California San Francisco. He received his PhD in human
1:27genetics from Tel Aviv University working on hereditary hearing loss he then did his post doc
1:36in functional genomics at the lawrence Berkeley National laboratory and the department of energy
1:43joint genome institute. the itube lab is focused on understanding the role of regulatory sequencing in
1:52human biology and disease through a combination of comparative genomic strategies biology
2:00chemical assays regulatory element analysis human patient samples mouse and fish genetic engineering
2:08technologies and massive parallel reporters assays they are working to elucidate mechanisms
2:16whereby genetic variation between these sequences lead to changes in human phenotypes.
2:22After this brief introduction i want to let you know a recorded version of the webinar
2:28will be available on the SRF website and on our YouTube channel. We also are live in
2:36Facebook right now. By the end of the presentation you will have the opportunity to
2:42get your questions answered. We love to hear from you. Please write your questions in the chat.
2:49For those who just joined us, welcome and I wanna let you know again the name of the talk today is
2:56Modulating gene regulation to treating dosage- associate diseases with Dr Nadav Ahituv and
3:05now I want to give him a welcome go ahead. Thank you thanks so much for having me here and Overview of talk
3:13it’s really a pleasure and hope to show you what we’re doing and also a project that we’ve just
3:20started actually on Syngap in the end and let me start my share screen. So it’s really important
3:28for me that people understand, and I don’t know at what level some people are, so I apologize
3:34that sometimes it’s too simple or or vice versa but the most important thing is please stop
3:40me at any time and ask questions via the chat or any other way that you can through this but
3:46really it’s more important that you understand than anything else so so stop me at any time don’t be shy there’s no such thing as a stupid question so really please and i’m i love it
3:56when people stop me in the middle so all right so i’ll start with that so and i’ll start first with
4:03some disclosures in terms of the companies i’m involved in and then I’ll move into
4:11the acknowledgements. And this work really started by an amazing and very talented
4:16postdoc in the lab Navneet Matharu who’s now a researcher and assistant professor at UCSF
4:21and where she wanted to tackle these diseases that are haploinsufficient similar to some of Haploinsufficiency: When one functional copy of a gene is not enough
4:29the Syngap mutations. And so the idea here is that we have two copies of our genes, one from our mom,
4:37and let me see if I can do a laser pointer here… okay, can you see my… um? We can see your
4:44mouse on the screen. Perfect! Okay great, so we have two copies of a gene, one from our mom and one from our dad,
4:51and when we have two copies that usually leads to normal gene levels – everything’s fine and so forth.
4:58But every so often we could have a loss-of-function mutation where only one copy
5:04is working versus another copy here. And then the problem with that is that we get 50% and basically
5:17(in terms of functional protein) and sorry i have to do something here for somebody
5:24quickly which will take me one second i apologize
5:29i don’t do this i’ll be in trouble there we go. Okay yeah, and so and if we have one functional
5:40copy we get 50% of a gene and for some genes this is perfectly fine having 50% but for some genes
5:48having 50% is sort of like running on empty, and that leads to human disease and it’s estimated
5:54that over 660 genes actually cause human disease due to what’s called haploinsufficiency when
6:02you have one gene that’s loss of function and Syngap some cases some mutations of course is
6:07one of these examples where you just have one copy and you have 50% of the protein being made.
6:15And the number is even estimated to be even higher so if people look at a whole genome sequencing
6:22data sets or whole exome where, you know, thousands of genomes have been sequenced
6:29and there’s over 3,000 genes where you never see this. You never see a loss of function mutation in
6:36one copy and so it could be even greater than the 660. 660 so far are known to lead to human
6:43disease. And so the current treatment for for these haploinsufficient genes, for most of them, is by
6:50drugs and the limitation there it’s very timely to make drugs, it’s costly, and it’s usually to treat
6:57the symptoms not to actually fix or cure the disease. Another approach that you probably may
7:03have heard of is a gene therapy where basically you can give, for example, extra copies of the gene
7:13to the patient and then that might be able to fix the disease. The problem there is sometimes
7:21dosage. It’s hard to control the amount. The tissue specificity: the gene can go into other tissues
7:27and with AAV (adeno-associated virus) which we’ll talk about quite a lot later on, there’s a limit
7:34to the amount of DNA that you can put into an AAV and that could be problematic for big
7:41genes. And Syngap for example is 4,200 base pairs which could be a problem in terms of
7:46fitting it into this virus. Another option which I’m assuming a lot of you have heard of
7:53is CRISPR where you can go and try to fix the actual mutation but the problem there is that the
8:01success rate of this is currently not that great and so it’s hard to fix in all the cells and also
8:08if people have different mutations and you need to sort of custom tailor, each sort of
8:15fix would be different between patients and that could be sometimes problematic in various ways.
8:22So about seven years ago this cool technology came out of UCSF from Jonathan Weissman, Wendell Lim,
8:29Stanley Qi and Luke Gilbert where they manipulated the Cas9 so it won’t be
8:37able to cut. So it’s sort of like, a it’s called a “dead-Cas9” basically. So it can bind to the DNA but
8:46it has a mutation in the scissors and so it cannot cut the DNA but it can bind. So what that allows
8:53you is to use it similar to a delivery truck to bring something specifically to a certain zip code
9:00in the genome to a certain location in the genome and you can connect stuff to it. So for example you
9:06can connect to it something that will force the gene to make less RNA and less protein and that’s
9:14been called “CRISPRi” for CRISPR interference or you can connect for example an activator to
9:20it that will force the gene to make more RNA and that’s been called “CRISPRa”: CRISPR activation.
9:29So if there’s one take-home slide that I hope you’ll get today is this one and CRISPRa as a therapeutic for haploinsufficiency?
9:35so when this came out and we thought “hey, this could be a great sort of a therapeutic
9:40for haploinsufficiency for these diseases” because here you still have this existing copy that’s
9:48perfectly fine it’s just giving you fifty percent. And so if we could target this existing copy for
9:55example with CRISPRa, which as I mentioned before, can force a gene to make more RNA and more protein,
10:05we might be able to increase these levels and fix the disease. I hope that’s clear for
10:12everybody. Again, this is the sort of the main take-home message that I hope you get.
10:18And so basically the idea is you still have that perfectly normal gene it’s just giving you 50%
10:27and so if we can again force it and squeeze out more RNA we might be able to fix the disease. And
10:32so when we started this about seven years ago we thought hard about what sort of disease we want
10:39to go after that will be simple and will be a good proof of principle for this and you know some phenotype that we can easily look at and so we came up with obesity as sort of a phenotype
10:51because the idea is even if we up regulate maybe just a little bit and we’re just here we might
10:57be able to see a nice quantitative change you know that the mouse is less obese just a little bit or so forth and that would be a very helpful phenotype to see if this idea could actually work.
11:10And so we chose two genes. I’ll tell you about one of them here. Both of them are part Sim1, an important obesity gene
11:17of the leptin pathway and again this is not as important. The main thing to understand here is
11:23that in adipose tissue we have this peptide, this hormone that gets secreted leptin when we eat
11:31and through a signaling cascade it tells us that we’re not hungry anymore and a lot of these mutations in almost all of these genes right here lead to severe obesity
11:42in humans and in mice also. And the gene that we chose to focus on here is SIM1 where there’s
11:50tons of mutations in obese individuals. If you take sort of the top one percentile of the population
11:56that is obese, and the highest body mass index, about two to three percent of them will have
12:02mutations in this gene in SIM1 and mutations in it are haploinsufficient. So if
12:10you have two copies of the gene you’re perfectly fine. If you have one copy of the gene and one, you
12:17know, is loss of function, so haploinsufficient, you have people who are extremely very obese
12:24and then no copies is actually lethal. So there’s nobody walking around with it because
12:31it’s very important for development of the hypothalamus and other organs in the body.
12:37So the idea is that we go here into these mice that are very similar that have basically one
12:45copy and are extremely obese and try to rescue their phenotype, their obesity, with this approach.
12:52And so when you have as I said one copy of this gene, one is loss of function, you have 50%
12:59protein and you have very obese mice. And so what we did was target a regulatory element,
13:06switches, that turn on this gene to force it to make more RNA. So we target the promoter
13:14which is right next to the gene and tells it to turn on with this CRISPR activation system
13:21and that hopefully should make the existing normal copy make more RNA and more protein.
13:29And we target another switch that’s called an enhancer. That could be very far away from a gene
13:35and in this case the enhancer is very specific to the hypothalamus where this gene is expressed
13:42and the idea is hopefully also here when we target this enhancer we force the gene to make this
13:49existing sort of normal copy to make more RNA and more protein and that will lead to more protein
13:55and no obesity in these mice. And so we got these mice and from a collaborator in Montréal that
14:05become extremely obese after 16 weeks. We made mice that have the Cas9 then the activator
14:17the thing that forces them to be to basically make more RNA and we cross them to these mice
14:25that become obese. And with Cas9 you need another component with CRISPR called the guide and so we
14:33made mice with another guide right here for the promoter or for the other switch the enhancer and
14:39our hope is that these guys become less obese than all of these guys here. And so this is a CRISPRa for either Sim1 promotor or enhancer rescues the obesity phenotype
14:46sort of the summary of this, where we target the promoter the switch that’s right next to the gene and force it to make more. And you can see here graphs of the body weight of these mice. So you
14:58can see mice here that are wild type that after 16 weeks weigh about you know 23 grams right here and
15:07these are the heterozygous mice the mice that are haploinsufficient that only have one functional copy and you can see they become extremely obese weighing about almost 50 grams after 16 days and
15:19then in yellow are the ones that we rescue with this CRISPRa and you can see that they look in
15:24terms of their body weight over 16 weeks just like normal mice. And the same for the other switch that
15:32enhancer that was very far away when we target it you can see that in green here the mice over 16
15:40weeks weigh exactly like the wild-type mice and not like the heterozygous mice
15:48and it’s always nice to show a picture so here you can see a mouse that genetically has only one copy
15:55so only one copy of this gene the other one is loss of function and you can see it’s extremely extremely obese for a mouse and here to the right you can see exactly the same mice in terms of the
16:07genotype which should be as obese as this mouse right here on the left but you can see it looks
16:14much more like a normal mouse because we managed to squeeze out more RNA and more protein from
16:21that existing normal copy in that mouse. So I’m happy to stop here if there’s any questions it’s
16:30important for me that, you know, this part will be understood and I see one question in the
16:38chat. “For haploinsufficiencies do you think that reducing the expression of one or more proteins
16:44direct protein-protein interactors or downstream could be treatment approach so total synthetic dosage not increase but the dosage of SynGAP and interactors would be more similar?” and so, yeah I
16:56mean, that’s definitely a potential approach and one that we’re actually trying here so if you
17:03know if i go back here to the cascade like can we rescue things here… so as I said mutations in
17:12any one of these genes leads to obesity this gene that we targeted is way downstream it’s it’s after
17:19all these genes and what we’re trying to do now is see if we can up regulate it does it help for
17:25example mutations in this gene like this one is way you know down sorry upstream and so if you
17:32have mutations in here you’re extremely obese but maybe if we up regulate this guy we can rescue it
17:38because the signaling pathway has to go through here so hopefully that answers the question.
17:45And another question in the chat from Janie is “Remind me, when you treated mice with CRISPRa, was
17:52it over different time points?” and that’s a great question. I’ll show you later on when we treat for
17:58another gene at later time points but with CRISPRa and and i’ll show you later with av we treated
18:07and i’ll show you an a v in a minute but we we treated only at four weeks and you can see that this is before they be this is the mice that are heterozygous that are haploinsufficient you
18:17can see they become extremely obese after that so we sort of treat it before they become obese
18:22and so we’re really interested also in treating you know somewhere around here to see whether we
18:27can rescue it or whether there’s some kind of a pathway that’s already sort of fixed and it’s too late to treat and so that’s some of the stuff that we’re doing now is trying to treat
18:38later in time to see can we rescue if there’s any other questions let me know
18:50okay so if there’s no other questions I’ll keep on moving on and again feel free to ask at any time
18:59and so this slide i’ll walk you through it it’s a little bit complicated but what I’m trying to show here is that the way we rescue
19:11is actually very tissue specific so the problem that I mentioned in the beginning with AAV is
19:16that it sometimes can go to other tissues and upregulate a gene in tissues where you don’t want
19:24one thing that we saw that’s advantageous to this approach also is the tissue specificity
19:29so the the gene that we targeted SIM1 is expressing the hypothalamus in the kidney
19:35but our CRISPR activation approach is expressed in all the tissues so i’m just showing you
19:41four tissues here but you can see that cast nine are all sort of CRISPRa is expressed in
19:47the hypothalamus in the kidney and the lung and the liver and all the tissues so technically we could be upregulating this gene in all the tissues which we don’t want and
19:59and so we looked are we up regulating in all the tissues so here I’m showing you just the expression of of this gene called SIM1 in normal mice and wild-type mice and it’s only expressed in
20:11the hypothalamus in the kidney but not in the lung in the liver this means below detectable levels so
20:16you know just like I said it’s only a hypothalamus in the kidney and we plot this as one and then we compare everything to the normal mice and so the the mice that are heterozygous that just have
20:28one copy of this gene have half expression as you would expect for haploinsufficient and they’re
20:34only expressing the hypothalamus in the kidney the mice that we up regulate and with the promoter
20:42with the switch that’s right next to the gene you can see that we’re only up regulating in the hypothalamus this gene and the kidney but not in the lung in the liver even though it’s
20:51expressed in the lung in the liver like all our CRISPR components are expressed in every tissue
20:57and so we see that it’s very tissue specific and then when we target this enhancer which is a
21:05switch that’s specific just to the hypothalamus we see that we’re only up regulating in the
21:10hypothalamus but not in the kidney and we think that it’s because when when you have
21:17this regulatory element the switch the DNA is much more open and when the switch is active
21:23and that allows the cas9 to bind to it and so for example here the the switch sort of is only
21:31open in the hypothalamus cas9 can only bind when it’s open in the hypothalamus and that
21:38and it only works there and so that provides you tissue specificity so by targeting specific
21:43switches that could provide us a tissue specific activation which is pretty good for
21:49for a therapeutic and I apologize if this wasn’t clear don’t don’t worry about it is there is
21:56there concern over over expression in something like the kidney here yes there is and and I’ll
22:02show you everything here is transgenic i’ll show you with AAV we could sort of modulate the over expression but there is concern we didn’t see any phenotypes here in the kidney at least not
22:12nothing observable the mice seemed fine but yeah it’s definitely a concern where you’re getting you know three threefold more than you should be getting so yeah okay so everything i’ve shown Can we develop it as a therapeutic?
22:25you was a transgenic approach where basically the mouse has the CRISPRa system from birth
22:32but we really wanted to go the distance and develop it as a therapeutic and I’m assuming a lot
22:38of you have heard of adeno-associated virus which is now used in a lot of clinical trials and
22:44the advantage of the adeno-associated virus is that it goes into the nucleus of the
22:51the cell but it doesn’t integrate into the genome and so it’s a sort of a more safer
22:56approach for a gene therapy and also it’s less immunogenic so it’s been used for a lot of
23:03clinical trials and some approved gene therapies have been done with adeno-associated virus.
23:10The issue that a adeno-associated virus has is that it it can only package a small sort of
23:17amount of DNA so only 4,700 base pairs or nucleotides is what it can package inside
23:24and you also have to take into account other DNA sequences that you need to get your transgene
23:30your DNA to be expressed and so if we go back to the genes that cause haploinsufficiency and Many genes cannot get packaged in an AAV
23:41660 or the 3,000 that are predicted that I mentioned before and we draw sort of our a red
23:48line in terms of their size on what would nicely fit into this adeno-associated virus you can see
23:55that there’s a lot of genes that lead to disease due to haploinsufficiency that will not fit into
24:01an AAV and Syngap is one example unfortunately that’s about 4,000 base pairs here so
24:09it’s on the cusp it may be but it’s pretty big to fit into an AAV along with all the other additional
24:16things that you need to make a strong sort of expression for this so another
24:25approach and that could be used is our CRISPRa approach for some of these long, large genes
24:31and so the idea is here that we made, at least for the obesity work, a virus that has the
24:41CRISPR system that activates that makes things and that increases expression and for it it needs this
24:48a guide that allows CRISPR to know where to bind and we made a guide for the promoter the switch
24:54that’s right next to the gene and a guide for the enhancer the switch that’s right next to
24:59the other farther away sort of switch and the idea is that we inject these two viruses into mice
25:07or these two viruses into the mouse and hope that they rescue their obesity phenotype via now again
25:15an adeno-associated virus approach and so we injected this into the hypothalamus of the mouse
25:24the mouse that’s has only one copy of SIM1 and becomes extremely obese and here we’re
25:30just showing you that she’s injecting it into the right place, into the hypothalamus and
25:37now we measure the levels of this gene SIM1 and again we plot a wild type the normal mice is one
25:46and the mice that have one copy you can see show half we had a sort of a negative control
25:53where we just inject the activation system but without the guide that tells it where to work
26:00and so here you can see that if we just inject the activation system without the guide that tells it where to bind in the genome we get also a half the expression but now when we add the promoter guide
26:14that tells it to bind right next to this genes in one or the enhancer guide that tells it to bind
26:19right next to this faraway switch of this gene in the hypothalamus, we’re now able to get expression
26:26of this gene that’s very similar to normal levels. So we’re managing to up regulated expression with
26:32AAV and get it to normal levels what about the phenotype here so we took these mice and again
26:38we inject at four weeks when before they become obese we wait a seven weeks and then we measure
26:46how much weight they gained in those in this time point and so you can see that the normal mice
26:54gain about five grams the mice that only have one copy of this gene gain quite a lot about 11 grams
27:02and our negative control where we just have the activator system but without the guide that tells
27:07it where to bind again similar to the heterozygous but are the ones that have the guide for the
27:14promoter or the enhancer the switch gained very similar to the normal mice so you can see that um
27:23we managed to basically rescue their obesity phenotype another thing we did was take these
27:28mice all the way to nine months from that single injection so we only inject it at
27:34four weeks of age and the advantage of AAV is that it can express the transgenes for the life
27:40of the mouse and so when we inject it at four weeks and then wait nine months
27:48we can see that our mice still look very normal in terms of their body weight so these are the
27:54normal mice these are the ones that have just one copy and you can see that they weigh quite a lot
28:01and these are again the negative control which is the activator but the ones where we injected both
28:06the promoter and the enhancer look just like wild-type mice in terms of their body weight
28:12with 30 grams so from that single injection at four weeks we have mice now at nine months that
28:19have the same body weight as the wild-type mice as the ones that have two copies of the gene Summary
28:25and so this looks like it could be a long-term therapeutic and for this obesity and gene
28:37so just to summarize this part when we did the transgenic and we saw that we could rescue
28:44this phenotype and what it allowed us since the transgenic approach we basically could
28:50up regulate in all the tissues what we saw uh was that we only upregulate the gene
28:57based on the regulatory element that we target so the switch sort of determines
29:02where we can up regulate or not only where it’s open and active and we up regulate
29:08which was good to see for tissue specificity and we have these mice and these vectors and
29:14we are using them for other diseases as I’ll show you in a minute and for me the most important was
29:20that the adeno-associated virus approach actually worked and rescued their obesity
29:26phenotype suggesting that this could be a viable therapeutic for a lot of these haploinsufficient
29:34diseases. So what I thought I’d show you today is how we’re following this up and a few
29:41other in one more gene but I’m happy to take stop here and take some questions about this.
29:47Yes there are. I was going to say it looks like there is one question in the chat
29:52So Pavel asked how do you gauge the frequency of this approach on nonsense versus missense
29:59mutations and what are your thoughts on allele-specific targeting possibilities? Great question
30:04Pavel so we have to make sure that the the other the allele is really loss of
30:11function because if it’s not I will also up regulate it and that’s not good. So
30:17your approach, at least for therapeutics, is the first thing is really make sure that the mutation
30:24is causing a loss of function mutation because yeah we don’t want to up regulate something that’s not loss of function so there it would not work and definitely allele-specific targeting
30:33is something that we’re thinking about also if for example if the switch that we’re targeting
30:39has a variant, a snip, that is only in the mutant but not in the normal allele or vice versa
30:49we could just target the normal allele with the guide and not the other one. So that’s that’s definitely something that we’re thinking about and I think and a lot of other people
30:59are thinking about in various other ways so it’s definitely approach that we would want to use.
31:06What about male mouse? Yeah I only showed so Roman asked what about the male mice I only showed the
31:11female but we had the same results with the males so exactly similar the nine months and a lot of
31:18these mice we had to take out and sacrifice to do a lot of these assays that I showed you like
31:23the up regulation or other stuff so we only had female mice that we took for the nine months but it worked everything else worked beautifully for the male mice exactly the same just that I didn’t
31:33want to overwhelm you with too many slides and and then Janie asked at cellular level what is
31:39the percent of cells that have AAV? That’s a great question. We we didn’t look we didn’t do
31:47any single cell on the hypothalamus to see what cells got the AAV and what didn’t and overall
31:54we saw broad as i showed if i go back here sorry and here you can see that overall we get a broad
32:04distribution of our AAV from our injections and it’s in the location in the pvn where we want in
32:10the hypothalamus and that being said we we didn’t look in a single cell manner and another thing is
32:17that i mentioned we injected two different viruses so we hope that both viruses go into every cell but it may not be the case in some cases but overall our sort of bulk up regulation
32:28as you can see here was enough to get levels at least on on the region of the hypothalamus
32:34that we looked at in bulk not on a single cell level of something that looks like a normal and
32:41like a normal mouse a mouse that has two copies of this gene
32:48okay no other questions so i’ll move into um another story that’s that’s I think more relevant for
32:57for Syngap and this is beautiful work by Serena Tamura who’s an amazing grad student in my
33:06lab who’s on the call now also today and will be much better to answer questions than me and then
33:12Perry Spratt was a grad student in Kevin Bender’s lab and along with many other people including
33:19Stephen Sanders here and this is also through the SCN2A families foundation and also through the
33:29SFARI the simons foundation autism research initiative where we got funded for this project
33:36and and the gene that we targeted here is SCN2A and it’s a sodium channel and if you look at
33:44this graph is showing you all the mutations that lead to autism and if you are more here
33:52to the right it’s much more common and SCN2A is probably one of the most common mutations
33:58and they lead to ASD but of course also Syngap as you can see is also here CHD8 and others and so
34:07we chose to go after this gene to see whether we can use the same approach that I just showed you
34:14to rescue some of the phenotypes that are known to be in this gene in mice.
34:23And in terms of SCN2A, mutations in this gene are associated with three different disorders so
34:31if you have for example increased function of the sodium channels then you have infantile epileptic
34:38encephalopathy and if you have a certain some de novo mutations lead to BIS and then if you
34:46have loss of function haploinsufficiency like I showed you for the vcdg, that leads
34:52more to ASD and intellectual disability and so we targeted of course the
34:59loss of function since that’s you know similar to the approach that we did before in terms of this
35:05sodium channel it’s a very important early in in development and in terms of action potential
35:13and so in the first year of life it has the main function in terms of action potential and in mice
35:20this is about one week in human it’s one year and then after that uh SCN8A takes over and then
35:27this sodium channel has an important role in back propagation and maintaining velocity as I’ll show
35:33you in a minute so this is beautiful work by Perry sprout and kevin bender’s lab who characterized
35:41mice who have only one copy of this gene and what you can see that early in life again like
35:48i mentioned there’s there’s differences in the action potential between the mice that have one
35:53copy versus two copies but then later on it seems to be fine but you have issues with velocity here
36:01where uh basically you see differences between the nor the sort of the ones that have two copies
36:06versus the ones that have one copy right here and these could be plotted as these nice squiggly
36:13lines showing differences here in velocity and so what we wanted to do is see can we rescue these
36:20phenotypes by upregulating the extra copy and um another thing that perry saw is that um the and
36:31neurons themselves were less mature in the mice that had one copy and that could be measured by
36:38nmda ratios where you can see that they’re much lower in mice that have only one copy versus mice
36:44that have two copies right here and we also try to see if we can rescue those phenotypes so serena
36:51worked hard to generate um an adeno-associated virus that targets the promoter of this gene and
36:58similar to the previous work that i showed you we used activator a virus and we inject it into mice
37:06and serena injects into one hemisphere and uses the other one as a control she waits for
37:13four weeks for the viruses to express and then she takes out the prefrontal cortex checks that
37:20she’s injecting and gets expression there checks that she’s up regulating and then along with kevin
37:26bender’s lab does electrophysiology to see are we rescuing the phenotype and this is just showing
37:32you that she’s injecting into the right place and that she manages to upregulate this gene with the
37:40crispr a approach and here both in wild type mice and these are in mice that have just one copy
37:49so what about phenotypes so as i mentioned the velocity and this is all in a sorry i
37:55forgot to mention this is all in adult mice so we did not inject in um in early mice yet
38:02we’re working on that but everything we’ve done is an adult mice where they’ve already
38:08started if i go back already past this page and now have just issues with velocity right here
38:15and so um if we go back here and what happens when we up regulate so you can see that we’re rescuing
38:24the velocity phenotype and here this is each one of each dot here is individual neurons and you can
38:30see that this looks more like mice that have two copies versus mice that have one copy right here
38:38and then what about amp nmda ratios which tells you about maturity of the neurons and you can see
38:44here that we are rescuing that phenotype also here and it’s looking much more like wild-type another
38:53concern that we have here and going back to the question before by peter is what happens if we
39:00up regulate too much and the problem that we have here that i mentioned in the beginning is if the channel works too well that could also lead to severe epilepsies and so we’re worried that if
39:12we up regulate too much that might be a problem and so to check that we took mice that have two
39:18copies of the gene and then we up regulate them with crispr a and to have twice as much of the
39:27gene itself and then we checked are we having do we have any phenotypes from this so this is again
39:33showing you the normal mice with two copies and one copy ones that we rescue and then in the mice
39:41that have two copies even if we up regulate we see that we’re getting similar velocities
39:48and also you can see it um throughout the different neurons that we check even though we’re
39:54upping it by twofold like twice as much and we think the reason for this is because it’s a sodium
40:01channel it has other subunits that basically bring it to the membrane and associate with it and
40:09even if we have too much of this sort of gene and this channel the other ones are at normal
40:15sort of normal wild-type levels and so because of that we don’t get as much of that channel
40:23in the membrane and that’s why we sort of get even if we up regulate it twice as much we still get a
40:30sort of a normal and velocity phenotype here due to that so just to summarize this part i’ve shown
40:38you that we can up regulate SCN2A in mice and i’ve shown you that we can improve the velocity
40:46in these mice with this upregulation and also the APMPA NMDA using this approach and as I showed
40:53you at the end in the mice that have two copies if we up regulate it too much we still see normal
41:01function of this channel and we think that’s due to just because the other subunits are sort
41:07of lower levels and so I think I’ll stop here for another question oh no question okay sorry
41:16and I’ll end with what we’re doing now for Syngap. So we were actually just awarded
41:26a grant from the Weill Neurohub, you can feel free to check out their website. This is a
41:34joint program between Berkeley UCSF and University of Washington and basically
41:42and we’re working with two other with a few other groups and both in Berkeley and the University of
41:48Washington in berkeley both with dan feldman and Helen Bateup and in the university of washington
41:54with um jay shandur’s lab and at UCSF with kevin bender and Stephan Sanders
42:00and we are awarded to do this to use exactly these similar approaches but for three different genes
42:07and one of them is actually Syngap and we’re actually now in the process of and
42:12finding guides and and optimizing CRISPRa conditions for Syngap we this just started so I
42:19sadly don’t have any information or any data yet to show you but we are now in the process
42:25of trying to optimize these conditions for CRISPRa and then it will go into the mice and see
42:31can we rescue some of these phenotypes and in particular Helen Bateup in Berkeley has
42:38characterized a lot of these in mice and and also in cell lines and a lot of the phenotypes in
42:43Syngap so it’s it’s really amazing to be able to work with her and and see can we basically
42:49rescue a lot of the phenotypes that we see in these mice and so that’s sort of the
42:54the goal of this again it just started a month ago and again the idea is we generate
43:02basically viruses specifically for Syngap and we’re going to inject and do very similar things
43:07that I’ve shown you for SCN2A but for Syngap and then I’ll end with the most important slide
43:15is just thanking members of my amazing labs our collaborators in particular kevin bender
43:23and stephen sanders on all these projects and of course dan feldman Helen Bateup labs and jason
43:30dewer labs and university of washington for this new neurohub project that we’re really excited
43:35to start with and of course our funding for the wild norah safari and all the other
43:41funding that we have in the lab so i’ll end there and very happy to answer more questionsQ&A
43:51and and then one question from janie could you say again who would you that will you work with on Syngap? Yeah so we will work with uh Jay Shendure uh on Syngap. Jay’s a genomicist and with him
44:03we’re what we’re trying to do is actually develop… so for every one of these genes when we try to
44:10find guides that upregulate the genes or try to find the best conditions for CRISPRa it
44:18actually takes quite a long time and so with Jay we’re working on developing technologies that can
44:24allow us to do it in one experiment that we can test for example 6,000 guides in one experiment and
44:31and that will save us a lot of time so then we’ll have already a whole list of guides for all the
44:36genes that we want to upregulate and we don’t need to optimize the conditions every once in a
44:41while again which could take like three months or so. So that’s what we’re doing with jake
44:48Thank you so much. That was great. Very good talk. Very, very nice. I have a question about the –
44:56if you are injecting with the CRISPRa you are injecting the hippocampus that is so deep in
45:03the brain and I didn’t saw that you measure in the cortex that is where most of the people
45:10measure this type of experiment and what is your explanation that for example the kidney
45:16was high or that is tough like because it’s very deep in the brain very localized
45:23down then… yeah so I apologize if I confuse you so the the first part
45:28that I showed until the AAV slide was we we we just did everything with a transgenic so the mice
45:35we made mice that have all the CRISPRa inside so there was no injections whatsoever the mice from the one cell stage already had all the CRISPRa and so that’s why the kidney was upregulated
45:48after that we we turned to then adeno-associated virus and just injected in the hypothalamus and
45:53we only stop regulation the hypothalamus and because it’s localized and same for SCN2A
45:59and SYNGAP1 that will do and so forth but the the initial work that we did with obesity
46:07was transgenic on and that allowed us to see the tissue specificity because the the CRISPRa was in all the cells because we basically made transgenic mice which
46:19basically to make transgenic mice you inject the construct in a one cell stage embryo
46:25and then it, you know, the the whole mouse has the gene in every possible tissue and so in every possible tissue you could up regulate but we did not see that so that sort
46:36of allowed us to see the tissue specificity which we couldn’t see with AAV because it’s localized
46:45i hope that’s clear. Yeah. Yeah and going forward we’re just doing AAV. That was just because it was a proof of principle.
46:54We wanted to see if there’s tissue specific if there’s an advantage for this approach in terms of tissue specificity if there is any other brain tissue that is high like the hippocampus or
47:07so for now depending on the gene we’re going to inject to you know the the best target in the
47:13brain and we’re also playing with different stereotypes so for example I’m assuming you heard
47:20about this php stereotype it’s great in mice it covers most of the brain actually and you get
47:26very nice expression but it only works in mice and only in certain types of my c-57 black mice and
47:33but there are others that are coming out and now there’s one article on bioarchive and it
47:38looks like a very good stereotype at least in macaques that is similar to this one that covers
47:45the brain much more you can envision injections in other locations not not directly but through
47:50other ways and so a lot of that will also be hopefully a trying to see can we improve
47:57and in terms of the the phenotype and we first want to get first the you know the pressure a
48:03conditions well that we know that we’re up regulating well and then we could play with various ways of delivery to see can we upregulate in more places or in the places that we want and
48:15and another thing we could do is is upregulate in certain locations versus others and see where are we rescuing where is the important region in the brain to rescue some of these phenotypes.
48:25Thank you. Dr. Ahituv I had just one quick question for you. You I think if I understood
48:32correctly earlier on you had mentioned with the CRISPR technology that it’s going to be mutation specific in terms of the actual treatment was that correct? So with this
48:44the standard CRISPR approach where you’re fixing the mutation and you have to basically
48:54if you’re using a standard approach there’s what’s called a donor plasmid that sort of goes in instead of the and fixes the mutation but you have to make that for each one there are other
49:05sort of flavors of CRISPRs like um base editing or CRISPR prime that you may have heard that can
49:10specifically fix a certain location and which which could be great the problem is for each
49:17mutation you’ll have to generate a different sort of guide and a different fix and and
49:23another concern that you could have with those is “DNA scar” what we call DNA “scars” that they
49:30they could fix the mutation but they could also cause mutations in other places yeah and that’s i mean again being optimized and worked and improved and but
49:44the advantage of this technique is that the the scissors of the cas9 are broken so it doesn’t
49:49cut the DNA whatsoever it just binds and and makes more copies so it could also bind in other places
49:55and lead to up regulation but we feel that you know and again I’m not as objective but we feel
50:03that that might be less severe usually than causing DNA scars but sort of an advantage and
50:09the main advantages you could have many mutations but for all of them you could just use this right
50:15if they’re loss of function you can use just this one moety and you don’t have to make
50:21taylor for each one the different ones so that that’s sort of the difference
50:26i see quite a lot of questions in the chat and from Pavel in your paper you mentioned
50:34nanoparticles as a delivery alternative to AAV. How realistic do you think this approach is
50:40versus AAV and what needs to happen to advance it and how long yeah so again great question Pavel
50:46we don’t have to deliver it with AAV we could do it with nanoparticles or any other thing that that people try to deliver and and you know DNA and a lot of work is beautiful work has been done
50:59on that you know even now with the COVID vaccine right or others and to deliver RNA and so that
51:05definitely could be a great approach and you know if people develop good delivery to the brain using
51:12these nano particles that that would be great. Another sort of worry I always have with AAV
51:18is that it’s going to be there all the time and if it up regulates like you mentioned before Peter and others too much that that could be a problem and so by
51:30giving it for example in the nanoparticle we could control and we could you know give it every so often and so forth so it could be a better way sort to control expression
51:39and so and so that might be so definitely you know i think that would be a good approach for this
51:47and janie asked one comment on the prevalence of Syngap it is way under diagnosed and we
51:54trend toward only those with strong symptoms of epilepsy getting diagnosed stay tuned for its actual prevalence when more extensive whole exome and genome yeah sequencing will be available
52:05and that would be great and again I should mention that our approach what I showed you
52:10works well for the loss of function and you got to make sure that it’s loss of function and Pavel asked this before and it’s a problem if it’s not a loss of function we
52:20we may be up regulating the bad allele also right and so and and so we got to be careful about that
52:28also but for loss of function and through these hopefully genome sequencing and exome
52:34sequencing we may know better about what these mutations are doing and then Heather I can take
52:41Dr Mefford off of mute real quickly if she wants to ask her question give me just one moment here
52:48dr Mefford yeah hi can you hear me? great nice work Nadav we actually just had Helen Bateup here to
52:56give a seminar earlier this week so it’s fun to hear about the new grant you got to the neurohub
53:02i was just curious how many genes you’re going to try to target through that grant? Is this like a large, you know, all neurodevelopmental genes screen or have you picked out a few favorites?
53:13Can you share that? sure sure so with the first approach of the grant first aim is
53:20to try to find them a lot of them sort of the reagents the guides like I mentioned it takes us a
53:26lot of times to optimize and so together with jay we’re we’re going to target about I forget the
53:33number of at least i think 300 genes are that lead to disease and in a high frequent manner just to
53:39find guides for them so that’s sort of the first approach and the the second name is really drill
53:46down on three genes and and try to use these approaches for them and the genes are SCN2A which
53:52I just showed you but doing more phenotyping there. SYNGAP1 which I mentioned and the third one
53:59is anchoring so those three genes are the ones that we’re going to drill down a bit more do much more extensive phenotyping, optimize our CRISPR reagents and injections and then similar
54:09to what I’ve showed you with SCN2A do the same for these other two genes that I mentioned
54:16perfect I think mike has a couple of questions as well mike yeah thank you can you guys hear me yeah
54:23yeah great so thanks Professor Ahituv that was awesome and I think just to calibrate for the
54:31parents on the phone who aren’t like basically what you’re presenting is something that could really worked because of both the specificity and the ability to up regulate so it’s super
54:42exciting and generally after webinars like this that are super exciting some parent calls me and says when will it be ready so and i obviously i have no clue so i i just a path for i mean so the
54:53question to you in a few parts is like and without raising expectations or making any promises like
54:59how long do you think this neurohub work is going to i mean i’m sure it’s years and then at what point do you think the Syngap work will be something that could go out to
55:08a company to actually start working on delivery and when would we see you know clinical trials
55:15and when could we hope just in terms of managing people’s expectations around this stuff and then
55:20after that hard question the other one is do you how will you think about the age of intervention
55:26and how how old will be too old or is there hope based on the the mouse work that maybe we could
55:33do rescue later in life i mean obviously these are next to possible questions but I thought I’d
55:38throw them at you since you’re clearly good at impossible things thanks mike and yeah so for the first question as you all probably know and sadly these things take
55:49time and and they won’t come from academia and and then you know they have to come from industry
55:55and and so on our end we we formed a company called regal therapeutics that that is sort of
56:01working on trying to take these into the clinic there are two other companies also that are
56:07are doing this one that i’ve been advising for a while and that one for for one disease and
56:14i think they’re close to being in clinical trials in a year from now and not not Syngap but but
56:21another one and so i think that will probably be the first clinical trial for this kind of approach
56:28and so hopefully in a year from now we’ll we’ll be able to see some results and and and
56:35you know with our company also we’re just gearing up and starting up so it will take time and
56:41sadly as these things do but again i think it’s only from industry you know in academia there’s only so much we could do and that will we’ll be able to move this forward
56:52and in terms of the second hard question in terms of what time to rescue and what age and
57:00i mean at least looking at the SCN2A it was very promising to see that we could we could rescue the
57:05phenotypes that we see in in the adult mice and we are going now to the earlier stages and we’ll see
57:12what you see there but one thing that really you know one of the things that made me so happy you
57:19know with coed and everything and all this here is i don’t know if you follow the the bio marin sorry not the by marine the ultragenics story about angelman syndrome with the the asos where
57:31where children were given at a much older age asos and and they see a very nice improvements
57:39in in the phenotype in their clinical and so so again this is a completely different disease and a
57:47completely different gene but but for me this was you know one of the rays of hope and and sunshine
57:54that i had this whole COVID year so there could be yeah yeah no I agree I follow fast and i’m
58:04i’m actually i listen i listen to everything that yale and ultra genics say because i think they’re amazing and i think the quote that came out of that one of the fast studies was
58:11that’s that i like to use is one of the doctors said we had no idea how plastic the brain was so
58:16you know as parents that that gives us a lot of hope i guess another question and i should have i’m just throwing hard questions at you because i know you can answer them but
58:24I hope i said we’re so grateful that that you and your colleagues are doing this work. It’s really exciting. You mentioned up front there are
58:35hundreds of haploinsufficiencies and yet you chose Syngap next and i’m
58:40i’m just curious like what was the thought process there was it the availability of science was it the fact that Helen and Stephan Sanders and others were already working on it? Or was it
58:47i mean what how did Syngap get lucky enough to be one of the three genes that are in this grant?
58:54yeah no great question i think for us it was in the availability of
59:01mouse models that we could you know in the end you want to go into the organism i
59:06i there’s so much i can do in a cell line but but you really want to if you can show it in
59:14on an organism level and the availability of cell lines and and characterize them and might sorry
59:20of mice and characterization of them so there’s actually a phenotype that we can go in and see
59:26that we can rescue and was very important when in serve our selection for this and then two of
59:32course was the the collaboration i i you know i should mention that this this wild neurohub grant
59:38you had to have three from the three sites so both from ucsf berkeley and um
59:44and then uw and and sort of you know and i kevin has been working a lot both with helen
59:52and was dance for dan feldman’s first phd student so it served was an
59:58easy survey tie with them to work on this and and helen’s been working and doing beautiful work on Syngap so i think that’s how what brought it together to Syngap.
1:00:11great can i get can i ask one more question sorry it’s too much fun um so so you’re working
1:00:17on you’re working on characterized mice which are which are which are knockouts or you know some of some of the fancier flocks i don’t even understand what those mice do but i don’t think
1:00:25we have that many patient or we don’t have enough in my opinion and i i don’t know enough science
1:00:30to really have an opinion but what i’m learning from talking to different companies is it would be great if we had more patient-derived cell lines and potentially patient-derived mice
1:00:40so that as things progress with various approaches those can those can be tested
1:00:47it it just in general like as a general thought does that does that make sense to you or do you think that might might be less true for this approach no i’d say that would be very helpful
1:00:58and again i i for me i’m you know my training is mouse so i’ve always want to see things in
1:01:04an organism but i think i mean even for scn2a what we’re doing now is we have two cell lines that are
1:01:10a lot loss of function of scn2a and and we are basically differentiating them into neurons and
1:01:17then test testing our CRISPRa approach on them and and that’s worked by Serena in lab to see can we
1:01:24rescue and so that you know could one you know if you want to get it to to you know therapeutic in
1:01:30the clinic one you wanna the guys are the sequence is very different for these switches between mice
1:01:36and humans right so you want to optimize you’ll need to optimize the guides on on human cell lines
1:01:42and two with this approach we can go you know all the way to at least some kind of a phenotype that
1:01:47we can see that we can rescue in these neurons and we are we are doing electrophysiology on them to see you know and we get them to a stage where they they fire and see electric you know
1:01:57we could see electrophysiology and and we could see differences between the and sort of the ones
1:02:04that have two copies versus one copy and now we’re trying to see can we rescue at least you know in
1:02:09in this cell culture system i think you know more and more there’s advance beautiful advances in in
1:02:15making brain organoids and and other sort of them tissues and in the lab from cells and so i think
1:02:23by having them that will be very helpful and some some things that usually come up when people do
1:02:30this research is um sometimes people prefer to have the same cell line but with the mutation so
1:02:37they make the mutation on the cell line because it provides a similar genetic background and then there’s no other backgrounds and and so so that’s sometimes also what what people like to
1:02:48do and with CRISPR now it’s much easier to do and so so another approach could be instead of
1:02:55you know having ipscs from from individuals you could also just generate mutations in
1:03:03ipscs and then you know start working with those that have the mutation the advantage there would be the genetic background is the same
1:03:17sorry i was muted there janie is a Syngap parent and geneticist i know that she’s been asking a lot of good questions here so i just pulled her off of mute to ask her next question
1:03:28hi uh thank you so much for all your work i was thinking about the phenotypic assays so
1:03:36do you already have phenotypic phenotypic assays for the drill down work on Syngap and you know the
1:03:42idea is that treatments the eventual treatments that seem to be coming pretty fast we’ll need
1:03:47biomarkers in order to tell if they are working or not and so development of biomarkers is something
1:03:53i’d love to understand and um even if you’re even if your assays are all lab specific you
1:04:00know wouldn’t really work in patient populations i was just wondering what you think the the assays will be and so and i think you may have already answered it since you said characterized
1:04:08mice right like if are you gonna use the same the same phenotypes that have already been characterized like the going back and forth in the y maze and stuff like that
1:04:18yeah so um so we are limited in you know both the funding and the time that we have for this grant
1:04:24but um our goal and as i said we just started and but our goal is first to optimize and and get the
1:04:31CRISPRa working nicely for Syngap and then once we do that we’ll pass it on to
1:04:38Helen who will do all the phenotyping but you know once we have all these reagents in place we’re
1:04:43happy to share them with with anyone who wants to use them for for any types of phenotyping you know
1:04:49in mice or that the ones that we’ll optimize will be mice but we’re you know we could also work quickly to do a newman man so he could be used in human cell lines or so forth and
1:04:59very happy to share in terms of or test any other biomarkers or anything that we can look at either in the mice or later on in in other cell types and but you know
1:05:09one once we have these in hand you know it’s very easy for us to to share and send around and give to to check for various other phenotypes and we’d love to collaborate with people to
1:05:23with this approach and then uh one last question that i didn’t put in the chat is with haploin
1:05:30sufficiencies have you have you considered or have you already been doing whole genome sequencing to see what the like say say you have a haploinsufficiency in five people and they
1:05:42have very different a very different range of effects right very different range of symptoms um can you do whole genome sequencing or some other kind of assay to see what the dosages of
1:05:53the protein and protein interactors so you know like kind of seeing are some kind of rescued by
1:05:59having less of something that it interacts with or or some worse because they have more
1:06:06yeah we we have not done it would be interesting to do sort of a phenotype genotype correlation on on the actual mutation in the expression and but uh or some kind of the rna-seq right to see
1:06:20expression levels you would need the specific tissue which of course is going to be hard impossible to get but and i i think that that would be very interesting we we are envisioning
1:06:32of course doing um you know for for mutations that are not clear loss of function or or even
1:06:37you know there could be some kind of a transcript is to really make sure that they are loss of function we can model them in some kind of a cell type first to see the expression and so that that
1:06:47would be important and and i think they’re also maybe get like mike said getting ips from from
1:06:53various patients would be very important to look at the differences in expression we could for example differentiate them into and neurons and and see the difference is an expression for
1:07:03each mutation make sure that it is a loss of function because as i mentioned our approach won’t work if it’s not a loss of function and but now we’re not doing that but i think yeah
1:07:13that’s definitely important to figure out and and on the industry side i think that that’s key also
1:07:20is really making sure that it’s a you know loss of function before you target anything because you
1:07:26could be doing more worse than harm and harm if you are targeting an allele that is expressed and
1:07:34should be still doing something that’s not that’s deleterious right but once you get five that you
1:07:42really know or loss of function it’s it would be interesting to have i you know human derived psc lines that you could then switch the mutations in and out and see you know is
1:07:53this line better with no matter what loss of function right and is this second line worse
1:07:58no matter which laws of function and then you can start interrogating them for what is up and down
1:08:03yeah you know what not what non-syn gap genes are up and down in there yeah yeah i think definitely
1:08:09if i’m trying to figure out also what what are the you know the other genes that interact what are we rescuing that with sim one we i didn’t show that just the amount of data but we did
1:08:18a lot of that also it’s a transcription factor in this case so it turns on a lot of genes and we looked at when we up regulate you know how it changes expression of a lot of other genes also
1:08:29and then are we are we sort of getting it closer to the expression of the oven sort of two copies
1:08:34of this gene so and yeah i think i definitely you know going back to mike’s question i i
1:08:40definitely think it would be very helpful to have and these um and cell lines because we you know
1:08:47you could test all that and look at differences in these mutations and what they’re doing and also
1:08:53as preliminary sort of trying to see can we up regulate not only rescuing and you know even the little phenotypes that we could do in cells would be helpful
1:09:09sorry i don’t see any other questions on the chat any last-minute questions
1:09:27this is a lot of science and for those of us who’ve been tracking you and the biohub it’s it’s it’s it’s truly incredible but i think it’s easy to miss how incredible it is because you
1:09:37you’ve covered so much i can i just ask you in 60 seconds or less to kind of
1:09:44in your own words because i don’t want to because 60 seconds about how long i have when i’m talking to different families about this stuff like could you could you try to just sum up like what makes
1:09:53this approach different in terms of everything from from the delivery to the specificity
1:09:59to the up regulating the haplo and then when i heard you answer my difficult question about time
1:10:04i know you can’t put a number on it but i think in terms of orders of magnitude we’re thinking years not decades so i guess the question is could you give us a quick summary and just
1:10:15something that i can quote or memorize to to try to describe this this project
1:10:24yeah so so i think i mean the the advantage of this approach is that um it does not cut the dna
1:10:31it just up regulates it can be used universally for any mutation that is a loss of function but
1:10:38you have to be sure that it’s loss of function and because and i i didn’t show too much data of this
1:10:44but because we’re targeting the the regulatory machinery the switches of the genes themselves
1:10:51and we think there’s an advantage in terms of tissue specificity and also sometimes we see
1:10:59like i showed you with scn2a that even if we up regulate too much it’s not and not too much of
1:11:06an issue is saying we saw for for this gene sim one which i didn’t go into detail too much but
1:11:13we think there’s some advantage also for ectopic expression and in terms of delivery there’s still a lot to do and and my worry with this approach is with av
1:11:24is that it’s going to be there all the time and so you need to have probably some kind of a kill neck
1:11:30switch if if you can if it’s doing something bad or use other things like pavel mentioned you know
1:11:38lipo proteins or sorry nanoparticles or other ways to deliver and this that could be used and
1:11:46i i feel and you know it’s still very preliminary very academic i’d say and then
1:11:54and you know i i think we’ll we’ll be much smarter in a few years from the work that
1:11:59industry is doing and as i mentioned there’s other than the company that we formed there’s two other companies so there’s three companies now there that i know of that
1:12:07are using this approach and and one in a year will hopefully be including full trials so
1:12:13and we could see does it actually work and but and you know until then i i have no idea and
1:12:21but you know i think it has it has a lot of potential and but there’s a lot of fears that
1:12:27i have with it as i mentioned is that with av in particular it’s there all the time and
1:12:35you know and if you mess something up it’s it for me it’s very frightening so and so i think having
1:12:43kill switches or having some kind of a safe way to control expression i think is really important
1:12:53that’s amazing thank you like i said before i’m i’m so grateful that you’re the thing gap’s on
1:12:58your radar and that you’re working on it so really appreciate your time today and sharing all this
1:13:05uh one one last question uh you mentioned that uh you guys saw the same change for nine months
1:13:11after the application to are you expecting that with time is the it will decrease the effect or
1:13:20so we saw we measured the levels in those mice of the cast of the crispr a and also of the gene
1:13:27the sim one that we up regulated and they were exactly the same as in you know in the beginning
1:13:32when we injected early and one advantage for neurons and this is the case also would be for
1:13:39syngap is that they’re non-dividing so av is there for the lifetime in dividing cells like
1:13:44um when people use av for liver and there is a an issue that you may at some point
1:13:51have to re-inject because the levels will go down because the cells divide and the av gets diluted
1:13:56and but with neurons that that’s an advantage for av again that it’s it’s there for the lifetime
1:14:04they don’t divide but again as i mentioned my biggest fear is it’s also a disadvantage where
1:14:09if something’s wrong it’s still there for the lifetime so so that’s my biggest concern for that
1:14:19any other questions just a standing ovation thank you so much yes we second that this is an excellent
1:14:30presentation really really appreciate it uh fascinating information covered thank you so much
1:14:37um we’ll go ahead and wrap if there are any other questions but thank you so much dr ahutuf
1:14:43and i think that’ll be it thank you so much thank you thanks for having me thanks everyone